[ad_1]
Article content continued
The ministry of health claims there is little published evidence of the clinical benefits of bamlanivimab and very limited safety data. The ministry also says that there are many challenges in using the drug because it has to be given intravenously.
It is recommended the drug be given to people who are COVID sick and at risk of being placed on a respirator. The treatment takes about an hour.
Eli Lilly says it has data to prove that when the drug is given in the early course of the disease it can help patients “clear the virus and reduces COVID-related hospitalizations.”
“While we acknowledge the early nature of the data, the use of bamlanivimab in Canada has been authorized by Health Canada under an Interim Order that was implemented with the express intent of expediting the availability and use of medicines to treat and prevent COVID-19.
“Now, with this medicine authorized for use in Canada and with supplies of this medicine now available for patients who need it, the fact that B.C.’s health care system has chosen not to use it is particularly disappointing … We hope the province will work quickly to revisit their decision.”
Health Canada has not yet returned a call asking where in Canada the drug was being used.
The use of bamlanivimab is being reviewed by the B.C. Remdesivir Review and Advisory Working Group.
dcarrigg@postmedia.com
[ad_2]
Source link
